New Therapies: Bridge Knowledge, Speed and Quality
Today, the pipeline of new therapies — including monoclonal antibodies, antibody fragments and cell and gene therapies — demands new methods and real-time analytics for process efficiency and predictability. How quickly and effectively can you deliver breakthrough, high-quality new therapies to market?
While advancements in the biopharma research and development (R&D) cycle exist, a new therapy can still take 10 to 12 years to progress from discovery to launch.
Disconnected processes, supply chain inefficiencies and manufacturing quality issues add to the complexity of accelerating life-saving treatments. Success depends on the ability to connect and collaborate in a single ecosystem.
To get to market first, biopharma companies need a digital backbone that bridges knowledge, quality and speed across the product lifecycle.
Enabling that will allow biopharma leaders to eliminate risks and prevent drug shortages. With improved efficiencies development and manufacturing timelines can significantly shorten, which translates into substantial cost savings. Ultimately, a connected digital backbone empowers biopharma leaders to drive innovation, optimize processes, and stay ahead in the race to bring novel therapies to market.
Download our whitepaper to find out more.
MGI promised to take genomics to the next level with its extensive product portfolio and...
The Micropore AXF (Advanced Cross Flow) range is expected to make a significant contribution to...
Now anyone can produce high-quality, reproducible NGS libraries at just a touch of a button.